Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Por:
Calafat, M, Torres, P, Tosca-Cuquerella, J, Sánchez-Aldehuelo, R, Rivero, M, Iborra, M, González-Vivo, M, Vera, I, de Castro, L, Bujanda, L, Barreiro-de Acosta, M, González-Muñoza, C, Calvet, X, Benítez, JM, Llorente-Barrio, M, Surís, G, Cañete, F, Arias-García, L, Monfort, D, Castaño-García, A, Garcia-Alonso, FJ, Huguet, JM, Marín-Jímenez, I, Lorente, R, Martín-Cardona, A, Ferrer, JA, Camo, P, Gisbert, JP, Pajares, R, Gomollón, F, Castro-Poceiro, J, Morales-Alvarado, J, Llaó, J, Rodríguez, A, Rodríguez, C, Pérez-Galindo, P, Navarro, M, Jiménez-García, N, Carrillo-Palau, M, Blázquez-Gómez, I, Sesé, E, Almela, P, de la Piscina, PR, Taxonera, C, Rodríguez-Lago, I, Cabrinety, L, Vela, M, Mínguez, M, Mesonero, F, García, MJ, Aguas, M, Márquez, L, Porto, MS, Pineda, JR, García-Etxebarría, K, Bertoletti, F, Brunet, E, Mañosa, M and Domènech, E
Publicada:
1 ene 2024
Resumen:
Background:Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF.Objectives:To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients.Design:Retrospective observational study.Methods:Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naive to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially).Results:Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission.Conclusion:The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents. Data from the ENEIDA registryBackground: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC), but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naive to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi, 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4%, in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.
Filiaciones:
:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Hosp Badalona Germans Trias & Pujol, Gastroenterol Dept, Badalona, Spain
Torres, P:
Hosp Badalona Germans Trias & Pujol, Gastroenterol Dept, Badalona, Spain
Tosca-Cuquerella, J:
Hosp Clin Univ Valencia, Gastroenterol Dept, Valencia, Spain
Sánchez-Aldehuelo, R:
Hosp Ramon & Cajal, Gastroenterol Dept, Madrid, Spain
Rivero, M:
Hosp Univ Marques de Valdecilla, Gastroenterol Dept, Santander, Spain
Inst Invest IDIVAL, Santander, Spain
Iborra, M:
Hosp Univ & Politecn La Fe, Gastroenterol Dept, Valencia, Spain
González-Vivo, M:
Hosp del Mar, Gastroenterol Dept, Barcelona, Spain
Vera, I:
Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda, Spain
de Castro, L:
Complexo Hosp Univ Vigo, Gastroenterol Dept, Vigo, Spain
Bujanda, L:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Biodonostia Hlth Res Inst, San Sebastian, Spain
Univ Pais Vasco Euskal Herriko Unibertsitatea, San Sebastian, Spain
Barreiro-de Acosta, M:
Complexo Hosp Univ Santiago, Gastroenterol Dept, Santiago De Compostela, Spain
González-Muñoza, C:
Hosp Santa Creu & Sant Pau, Gastroenterol Dept, Barcelona, Spain
Calvet, X:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Corp Sanitaria Univ Parc Tauli, Gastroenterol Dept, Sabadell, Spain
Benítez, JM:
Hosp Univ Reina Sofia, Gastroenterol Dept, Cordoba, Spain
Inst Maimonides Invest Biomed Cordoba, Cordoba, Spain
Llorente-Barrio, M:
Hosp Univ Miguel Servet, Gastroenterol Dept, Zaragoza, Spain
Surís, G:
Hosp Univ Bellvitge, Gastroenterol Dept, Barcelona, Spain
Cañete, F:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Hosp Badalona Germans Trias & Pujol, Gastroenterol Dept, Badalona, Spain
Arias-García, L:
Hosp Univ Burgos, Gastroenterol Dept, Burgos, Spain
Monfort, D:
Consorci Sanitari Terrassa, Gastroenterol Dept, Terrassa, Spain
Castaño-García, A:
Hosp Univ Cent Asturias, Gastroenterol Dept, Oviedo, Spain
Garcia-Alonso, FJ:
Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid, Spain
Huguet, JM:
Hosp Gen Univ Valencia, Gastroenterol Dept, Valencia, Spain
Marín-Jímenez, I:
Hosp Gregorio Maranon, Gastroenterol Dept, Madrid, Spain
Lorente, R:
Hosp Gen Univ Ciudad Real, Gastroenterol Dept, Ciudad Real, Spain
Martín-Cardona, A:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Hosp Univ Mutua Terrassa, Gastroenterol Dept, Terrassa, Spain
Ferrer, JA:
Hosp Univ Fdn Alcorcon, Gastroenterol Dept, Alcorcon, Madrid, Spain
Camo, P:
Hosp Gen San Jorge, Gastroenterol Dept, Huesca, Spain
Gisbert, JP:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Hosp Univ La Princesa, IIS Princesa, Gastroenterol Dept, Madrid, Spain
UAM, Madrid, Spain
Pajares, R:
Hosp Univ Infanta Sofia, Gastroenterol Dept, Madrid, Spain
Gomollón, F:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Hosp Clin Univ Lozano Blesa, Gastroenterol Dept, IIS Aragon, Zaragoza, Spain
Castro-Poceiro, J:
Hosp Clin Barcelona, Gastroenterol Dept, Barcelona, Spain
Morales-Alvarado, J:
Hosp Gen Granollers, Gastroenterol Dept, Granollers, Spain
Llaó, J:
Althaia Xarxa Assistencial Manresa, Gastroenterol Dept, Manresa, Spain
Rodríguez, A:
Hosp Gen Univ Alacant, Gastroenterol Dept, Alacant, Spain
Rodríguez, C:
Complejo Hosp Navarra, Gastroenterol Dept, Pamplona, Spain
Pérez-Galindo, P:
Complejo Hosp Univ Pontevedra, Gastroenterol Dept, Pontevedra, Spain
Navarro, M:
Hosp Moises Broggi, Gastroenterol Dept, St Joan Despi, Spain
Jiménez-García, N:
Hosp Gen Univ Elx, Gastroenterol Dept, Elx, Spain
Carrillo-Palau, M:
Hosp Univ Canarias, Gastroenterol Dept, San Cristobal la Laguna, Spain
Blázquez-Gómez, I:
Hosp Univ Torrejon, Gastroenterol Dept, Torrejon, Spain
Sesé, E:
Hosp Arnau Vilanova, Gastroenterol Dept, Lleida, Spain
Almela, P:
Hosp Gen Univ Castello, Gastroenterol Dept, Castellon de La Plana, Spain
de la Piscina, PR:
Hosp Univ Alava, Gastroenterol Dept, Vitoria, Spain
Taxonera, C:
Hosp Clin San Carlos, Gastroenterol Dept, Madrid, Spain
Rodríguez-Lago, I:
Hosp Univ Galdakao, Gastroenterol Dept, Biocruces Bizkaia HRI, Galdakao, Spain
Cabrinety, L:
Hosp Univ Joan XXIII, Gastroenterol Dept, Tarragona, Spain
Vela, M:
Hosp Univ Nuestra Senora Candelaria, Gastroenterol Dept, Santa Cruz de Tenerife, Spain
Mínguez, M:
Hosp Badalona Germans Trias & Pujol, Gastroenterol Dept, Badalona, Spain
Hosp Clin Univ Valencia, Gastroenterol Dept, Valencia, Spain
Mesonero, F:
Hosp Ramon & Cajal, Gastroenterol Dept, Madrid, Spain
García, MJ:
Hosp Univ Marques de Valdecilla, Gastroenterol Dept, Santander, Spain
Inst Invest IDIVAL, Santander, Spain
Aguas, M:
Hosp Univ & Politecn La Fe, Gastroenterol Dept, Valencia, Spain
Márquez, L:
Hosp del Mar, Gastroenterol Dept, Barcelona, Spain
Porto, MS:
Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda, Spain
Pineda, JR:
Complexo Hosp Univ Vigo, Gastroenterol Dept, Vigo, Spain
García-Etxebarría, K:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Biodonostia Hlth Res Inst, San Sebastian, Spain
Univ Pais Vasco Euskal Herriko Unibertsitatea, San Sebastian, Spain
Bertoletti, F:
Hosp Santa Creu & Sant Pau, Gastroenterol Dept, Barcelona, Spain
Brunet, E:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Corp Sanitaria Univ Parc Tauli, Gastroenterol Dept, Sabadell, Spain
Mañosa, M:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Green Published, gold
|